Wolverine (bpc 5mg, tb500 5mg)

Wolverine Recovery Bundle - BPC-157 5mg TB-500 5mg research peptides by Blueprint Labs

Rated 4.3 out of 5

Wolverine (bpc 5mg, tb500 5mg)

$55.00

🧬 Chemical Overview

🧰 Wolverine Bundle: Two individually-viated compounds — BPC-157 (5mg) and TB-500 (5mg) — supplied as a dual-compound research kit.

BPC-157 — 5mg Vial

Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Molecular Weight	1419.55 g/mol
CAS Number	137525-51-0
Purity	≥98% (HPLC + LC-MS verified)

TB-500 (Thymosin Beta-4) — 5mg Vial

Active Motif	Ac-Ser-Asp-Lys-Pro (SDKP; bioactive N-terminal fragment)
Full Tβ4 MW	4963.5 g/mol
CAS Number	77591-33-4
Purity	≥98% (HPLC + LC-MS verified)

⚗️ Mechanism of Action

Mechanism of Action

BPC-157 acts via the nitric oxide (NO) system through eNOS/Src-Caveolin-1 pathway activation, upregulates VEGFR2-mediated angiogenesis, and modulates FAK-paxillin cytoskeletal signaling, driving fibroblast proliferation and ECM remodeling in experimental wound models.

TB-500 (Thymosin Beta-4) primary mechanism involves high-affinity monomeric G-actin binding (Kd ~0.5 μM), regulating the G-actin:F-actin equilibrium and cytoskeletal dynamics. By sequestering G-actin, Tβ4 modulates actin polymerization, lamellipodia formation, and directed cell migration — central to tissue repair in in vitro scratch assay models.

TB-500 also suppresses NF-κB with downstream reductions in TNF-α, IL-1β, and IL-6, activates the PI3K/Akt survival pathway, and upregulates VEGF expression in angiogenesis assays. The Ac-SDKP tetrapeptide released from the Tβ4 N-terminus is itself biologically active and studied for anti-fibrotic signaling.

📋 Research Applications

Research Applications

Dual-peptide cytoskeletal and wound-repair research protocols
TB-500: G-actin sequestration and actin polymerization dynamics studies
TB-500: Cell migration and lamellipodia formation assays
TB-500: NF-κB inflammatory pathway suppression research
TB-500: PI3K/Akt cardiomyocyte survival and cardioprotection studies
BPC-157: VEGFR2, eNOS, and NO-pathway signaling studies

📖 Peer-Reviewed References

Peer-Reviewed References

Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421–429.
Sosne G, Qiu P, Shafiee A. Thymosin β4 promotes dermal healing. Ann N Y Acad Sci. 2012;1269:68–76.
Bock-Marquette I, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration. Nature. 2004;432(7016):466–472.
Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 in clinical trials. Curr Pharm Des. 2018;24(18):1942–1955.

🧪 Testing & COA

Testing & Supply Specifications

Every Blueprint Labs batch is independently verified by third-party analytical laboratories prior to release. Identity and purity confirmed via HPLC and mass spectrometry. Full batch records maintained for chain-of-custody traceability.

Testing LaboratoriesFreedom Diagnostic, Janoshik (per compound)

Analytical MethodsHPLC (UV), LC-MS identity confirmation

Batch ReferenceBPC-157 Batch #BPC108

Purity Standard≥98% confirmed prior to release

📄 View Certificate of Analysis

Research Use Only. This product is intended strictly for laboratory and in vitro research purposes. Not for human consumption, veterinary use, or any clinical application. Not intended to diagnose, treat, cure, or prevent any disease or medical condition. All statements are informational and have not been evaluated by the FDA.

86 in stock

Buy Now